Title

Response assessment criteria for brain metastases: proposal from the RANO group.

Document Type

Article

Publication Date

6-1-2015

Publication Title

The lancet oncology

Abstract

CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from most clinical trials, but their inclusion is now becoming more common. The medical literature is difficult to interpret because of substantial variation in the response and progression criteria used across clinical trials. The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases. Previous efforts have focused on aspects of trial design, such as patient population, variations in existing response and progression criteria, and challenges when incorporating neurological, neuro-cognitive, and quality-of-life endpoints into trials of patients with brain metastases. Here, we present our recommendations for standard response and progression criteria for the assessment of brain metastases in clinical trials. The proposed criteria will hopefully facilitate the development of novel approaches to this difficult problem by providing more uniformity in the assessment of CNS metastases across trials.

Medical Subject Headings

Brain Neoplasms; Central Nervous System; Clinical Trials as Topic; Glioma; Humans; Magnetic Resonance Imaging

PubMed ID

26065612

Volume

16

Issue

6

First Page

270

Last Page

278

Share

COinS